A couple of days ago someone on another site had a response from Janssen re Evorel conti and I am sure it's OK to reproduce it here as it's a standard letter with nothing personal. Apologies if this has been written before as it's a long thread - which I have read but not all in one go so have forgotten some of the posts! (Brain or rather memory doesn't work like it used to now I'm getting older!). I have put in bold the important bit. Note they state also that the unavailability of Femseven is only partly the reason for increased demand...
"Thank you for your recent enquiry regarding Evorel®(estradiol) and the reasons behind the interruption to supply.
As you may be aware, the stock situation around estradiol transdermal patches in Europe has evolved rapidly over recent months and continues to do so, impacting several manufacturers, including Janssen.
We continue to experience an unprecedented increase in demand for the Evorel range of products, due in part to the lack of availability of alternative hormone replacement therapies (HRT) not produced by Janssen. So far this year, demand in the UK has already exceeded that of the whole of 2018 depleting all surplus stock. As a result, we are unfortunately anticipating a complete interruption to supply across the product range from October 2019, although certain patches may stock out earlier than this date. We are working on a return to full supply by mid-2020.
We understand the urgency of the situation and have already taken steps to prolong continuity of supply for as long as possible; including diverting as much Evorel stock as possible to the UK from countries where demand is not as high. This additional stock consists largely of Evorel Conti patches which has the highest demand. We have, and will continue to, allocate all available stock to those countries with the highest unmet need including the UK.
Evorel products are still being supplied whilst available. If your pharmacy is encountering problems in ordering the product, they can contact our Customer Services team directly on 01494 567400 for further information on availability. We also recommend that you consult your healthcare professional directly with regard to HRT options and potential alternatives.The charity organization British Menopause Society, an independent service to advise, reassure and educate women have published a summary update which is very helpful and provides up to date information on availability of HRT products in the UK:
https://thebms.org.uk/The ABPI Code of Practice for the Pharmaceutical Industry does not allow pharmaceutical companies to provide medical advice to patients, comment on their personal medical matters, or suggest the most appropriate medicine for their treatment. We recommend you contact your prescribing/treating physician, GP, pharmacist or nurse to discuss such matters instead; they will have access to your medical history and are best placed to advise you on the most appropriate course of action. If they require specialist information on any of our products we would be happy to help.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on +44 (0) 1494 567447.
By reporting side effects you can help provide more information on the safety of this medicine.
I hope this information is useful.
Sent on behalf of
Medical Information Department
Janssen-Cilag Ltd
50-100 Holmers Farm Way
High Wycombe
Bucks
HP12 4EG
Tel: +44 (0) 1494 567 444
Fax: +44 (0) 1494 567 445
Hope this helps

Hurdity x